Mutual of America Capital Management LLC Has $2.68 Million Stake in Haemonetics Co. (NYSE:HAE)

Mutual of America Capital Management LLC decreased its stake in shares of Haemonetics Co. (NYSE:HAE) by 4.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 31,365 shares of the medical instruments supplier’s stock after selling 1,612 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Haemonetics were worth $2,682,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Stifel Financial Corp grew its position in shares of Haemonetics by 2.5% during the 1st quarter. Stifel Financial Corp now owns 4,891 shares of the medical instruments supplier’s stock worth $405,000 after buying an additional 119 shares during the period. Knights of Columbus Asset Advisors LLC lifted its holdings in shares of Haemonetics by 1.3% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 10,005 shares of the medical instruments supplier’s stock worth $896,000 after purchasing an additional 128 shares in the last quarter. Meeder Asset Management Inc. lifted its holdings in shares of Haemonetics by 65.2% in the 4th quarter. Meeder Asset Management Inc. now owns 342 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 135 shares in the last quarter. Metropolitan Life Insurance Co NY lifted its holdings in shares of Haemonetics by 4.5% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 3,202 shares of the medical instruments supplier’s stock worth $252,000 after purchasing an additional 138 shares in the last quarter. Finally, Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 21.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 786 shares of the medical instruments supplier’s stock worth $67,000 after purchasing an additional 140 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HAE. Barrington Research reiterated an “outperform” rating and issued a $105.00 target price on shares of Haemonetics in a report on Friday, April 12th. TheStreet cut Haemonetics from a “b-” rating to a “c+” rating in a report on Thursday, February 29th. Finally, StockNews.com cut Haemonetics from a “buy” rating to a “hold” rating in a report on Friday, March 22nd.

Haemonetics Price Performance

Shares of NYSE:HAE opened at $83.50 on Friday. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. The stock’s fifty day simple moving average is $78.83 and its two-hundred day simple moving average is $82.78. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $95.26. The stock has a market cap of $4.24 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 1.99 and a beta of 0.36.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.10. Haemonetics had a return on equity of 22.37% and a net margin of 9.97%. The business had revenue of $336.20 million for the quarter, compared to analysts’ expectations of $320.84 million. During the same period last year, the business earned $0.85 EPS. The business’s revenue was up 10.1% on a year-over-year basis. As a group, analysts forecast that Haemonetics Co. will post 3.95 EPS for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.